Tiziana Life Sciences (TLSA) announced a significant milestone in its clinical development program for Alzheimer’s disease. The Company has successfully dosed the first patient with moderate Alzheimer’s disease using intranasal foralumab at Brigham and Women’s Hospital in Boston, Massachusetts following on from their baseline PET scan.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TLSA:
- Tiziana Life Sciences Expands MS Clinical Trial Network
- Tiziana Life Sciences expands Phase 2 trial for non-active SPMS
- Tiziana Life Sciences Secures ALS Trial Funding
- Tiziana Life Sciences announces ALS trial grant awarded by ASL Association
- Tiziana Life Sciences Highlights Advancements at BIO-Europe 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
